Validation of dose distribution computation on sCT images generated from MRI scans by Philips MRCAT

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F19%3A10398628" target="_blank" >RIV/00179906:_____/19:10398628 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=kbHGimSA3S" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=kbHGimSA3S</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.rpor.2019.02.001" target="_blank" >10.1016/j.rpor.2019.02.001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Validation of dose distribution computation on sCT images generated from MRI scans by Philips MRCAT

Popis výsledku v původním jazyce

Aim: To evaluate calculation of treatment plans based on synthetic-CT (sCT) images generated from MRI. Background: Because of better soft tissue contrast, MR images are used in addition to CT images for radiotherapy planning. However, registration of CT and MR images or repositioning between scanning sessions introduce systematic errors, hence suggestions for MRI-only therapy. The lack of information on electron density necessary for dose calculation leadsto sCT (synthetic CT) generation. This work presents a comparison of dose distribution calculated on standard CT and sCT. Materials and methods: 10 prostate patients were included in this study. CT and MR images were collected for each patient and then water equivalent (WE) and MRCAT images were generated. The radiation plans were optimized on CT and then recalculated on MRCAT and WE data. 2D gamma analysis was also performed. Results: The mean differences in the majority of investigated DVH points were in order of 1% up to 10%, including both MRCAT and WE dose distributions. Mean gamma pass for acceptance criteria 1%/1 mm were greater than 82.5%. Prescribed doses for target volumesand acceptable doses for organs at risk were met in almost all cases. Conclusions: The dose calculation accuracy on MRCAT was not significantly compromised in the majority of clinical relevant DVH points. The introduction of MRCAT into practise would eliminate systematic errors, increase patients&apos; comfort and reduce treatment expenses. Institutions interested in MRCAT commissioning must, however, consider changes to established workflow. (C) 2019 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Název v anglickém jazyce

Validation of dose distribution computation on sCT images generated from MRI scans by Philips MRCAT

Popis výsledku anglicky

Aim: To evaluate calculation of treatment plans based on synthetic-CT (sCT) images generated from MRI. Background: Because of better soft tissue contrast, MR images are used in addition to CT images for radiotherapy planning. However, registration of CT and MR images or repositioning between scanning sessions introduce systematic errors, hence suggestions for MRI-only therapy. The lack of information on electron density necessary for dose calculation leadsto sCT (synthetic CT) generation. This work presents a comparison of dose distribution calculated on standard CT and sCT. Materials and methods: 10 prostate patients were included in this study. CT and MR images were collected for each patient and then water equivalent (WE) and MRCAT images were generated. The radiation plans were optimized on CT and then recalculated on MRCAT and WE data. 2D gamma analysis was also performed. Results: The mean differences in the majority of investigated DVH points were in order of 1% up to 10%, including both MRCAT and WE dose distributions. Mean gamma pass for acceptance criteria 1%/1 mm were greater than 82.5%. Prescribed doses for target volumesand acceptable doses for organs at risk were met in almost all cases. Conclusions: The dose calculation accuracy on MRCAT was not significantly compromised in the majority of clinical relevant DVH points. The introduction of MRCAT into practise would eliminate systematic errors, increase patients&apos; comfort and reduce treatment expenses. Institutions interested in MRCAT commissioning must, however, consider changes to established workflow. (C) 2019 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Reports of Practical Oncology and Radiotherapy

ISSN

1507-1367

e-ISSN

—

Svazek periodika

24

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

6

Strana od-do

245-250

Kód UT WoS článku

000461452700017

EID výsledku v databázi Scopus

2-s2.0-85062042237